Provider of Quality Medical Diagnostic & Research Products



Welcome to 2015 with our latest newsletter full of interesting news from Quadratech
Our latest newsletter full of interesting news
Quadratech is sponsoring a Microparticles Meeting at the University of Leicester Tuesday 21st May 2013 A series of presentations by leading microparticles researchers from the UK and Amsterdam Medical Centre
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Raps M et al, 2013, Throm Haemost 109(4):[ahead of print] "The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk of venous thrombosis associated with oral contraceptives"
Molecular Circuits in Thrombosis and Inflammation. Esmon CT, 2013, Throm Haemost 109 (3):416-420 "In addition to the direct prothrombotic activity of histone-DNA complexes, the complexes trigger activation of the toll-like receptors 2, 4 and 9 thereby increasing inflammatory cytokine formation and fostering thrombotic responses through the mechanisms mentioned previously."
Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk. Jose M et al, PLOS ONE 1 September 2012 Volume 7 Issue 9
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
A study of patients in three different monitoring settings showed domiciliary-based patients had the poorest anticoagulation control.
What is already known about this subject: Observation from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjects • Variability of response to clopidogrel active metabolite and reduced platelet inhibition lead to increased adverse cardiovascular events in patients with acute coronary syndromes
What is already known about this subject: A number of pharmacokinetics studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. What this study adds: This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin.